The German speciality pharma company is taking ownership of Atacand (candesartan) and Atacand Plus (candesartan and hydrochlorothiazide) for $250 million upfront, with another $150 million due to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results